2,11β,17α,21-Tetrahydroxy-pregn-4-en-3,20-dion | 10326-30-4

• 分子结构分类: 有机化合物
• 英文名称: 2,11β,17α,21-Tetrahydroxy-pregn-4-en-3,20-dion
• 英文别名: b-Hydroxycortisol；(8S,9S,10R,11S,13S,14S,17R)-2,11,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
• CAS: 10326-30-4
• 化学式: C₂₁H₃₀O₆
• 分子量: 378.466
• InChiKey: RORUGVXGZMMYON-ZHAFKKQJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  27
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  115
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• COMPOSITIONS COMPRISING 4-(2-(5-BROMO-4-(1-CYCLOPROPYLNAPHTHALEN-4-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETAMIDO)-3-CHLOROBENZOIC ACID AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND METHODS FOR PREPARING AND USING SAME
  申请人：Quart Barry D.

  公开号：US20110244049A1

  公开（公告）日：2011-10-06

  The present invention relates to compositions comprising 4-(2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4H-1,2,4-triazol-3-ylthio)acetamido)-3-chlorobenzoic acid or pharmaceutically acceptable salts thereof, and to the preparation and use of such compositions, in particular for the treatment of diseases.

  本发明涉及含有4-(2-(5-溴-4-(1-环丙基萘-4-基)-4H-1,2,4-三唑-3-基硫代)乙酰氨基)-3-氯苯甲酸或其药学上可接受的盐的组合物，以及这种组合物的制备和使用，特别是用于治疗疾病。
• Use and regeneration of reagents using coupled reactions and permselective barriers
  申请人：BEND RESEARCH, INC.

  公开号：EP0349204A2

  公开（公告）日：1990-01-03

  A process is disclosed for the use and regeneration of valuable reagents, including coenzymes, using permselective barrier-assisted coupled reactions, most involving redox couples.

  本发明公开了一种利用过选择性屏障辅助偶联反应（大多涉及氧化还原偶联反应）使用和再生有价值试剂（包括辅酶）的工艺。
• Hybrid proteins of beta-lactamase class A
  申请人：Université de Liège

  公开号：EP1564286A1

  公开（公告）日：2005-08-17

  The present invention refers to a recombinant nucleotide sequence which codes upon expression for at least a part of a hybrid β-lactamase class A protein, wherein in that the β-lactamase class A protein is bearing at least one heterologous sequence in a region located between two neighboring alpha helices of the β-lactamase sequence, wherein the region is selected from: a) the region forming a juncture between alpha helix 8 and alpha helix 9 of the TEM-1 β-lactamase; b) the region forming a juncture between the alpha helices of homologous β-lactamases class A, which correspond to the alpha helix 8 and alpha helix 9 of the TEM-1 β-lactamase.

  本发明是指一种重组核苷酸序列，它在表达时编码至少一部分杂交β-内酰胺酶A类蛋白质，其中β-内酰胺酶A类蛋白质在位于β-内酰胺酶序列的两个相邻α螺旋之间的区域中含有至少一个异源序列，其中该区域选自： a) 在 TEM-1 β-内酰胺酶的α螺旋 8 和α螺旋 9 之间形成连接的区域； b) 与 TEM-1 β-内酰胺酶的α螺旋 8 和α螺旋 9 相对应的同源 β-内酰胺酶 A 类的α螺旋之间的连接区域。
• FMO3 inhibitors for treating pain
  申请人：Akron Molecules GmbH

  公开号：EP2674161A1

  公开（公告）日：2013-12-18

  The present invention relates to new therapies to treat pain and related diseases, as well as pharmaceutical compounds for use in said therapies.

  本发明涉及治疗疼痛和相关疾病的新疗法，以及用于上述疗法的药物化合物。